Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-881 in Advanced Solid Tumors and Gliomas with IDH1/2 Mutations
NCT02481154Phase 1Completed
- Sponsor
- Servier
- Start
- Jun 2015
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vorasidenib in glioma and solid tumor, sponsored by Servier. Primary endpoints: Incidence of Adverse Events at 26 weeks and Maximum Tolerated Dose and/or Recommended Phase II Dose at 26 weeks. Started Jun 2015; status: completed.
02
Drugs
vorasidenib
03
Conditions
gliomasolid tumor
Beyond the preview
Go deeper on NCT02481154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02481154.